Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRMT6 | Q96LA8 | 1/20 | 0.37 |
| ▸ | ADORA1 | P30542 | 4/20 | 0.36 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.36 |
| ▸ | ADORA2A | P29274 | 2/20 | 0.36 |
| ▸ | BMPR1B | O00238 | 1/20 | 0.35 |
| ▸ | P2RY12 | Q9H244 | 2/20 | 0.35 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13559220 | 1.00 | PRMT6 (0.37) | PRMT6ADORA1ADORA3ADORA2ABMPR1B | |
| SCHEMBL13787608 | 0.90 | RAB9A (0.36) | — | |
| SCHEMBL15962174 | 0.84 | NR1H4 (0.40) | — | |
| SCHEMBL27518665 | 0.79 | ADORA1 (0.43) | ADORA1ADORA3ADORA2AADORA2B | |
| SCHEMBL28423217 | 0.76 | ADORA1 (0.40) | ADORA1ADORA3ADORA2AP2RY12ADORA2B | |
| SCHEMBL7203906 | 0.75 | ADORA1 (0.42) | ADORA1ADORA3ADORA2AADORA2B | |
| SCHEMBL29313494 | 0.74 | BMPR1B (0.56) | ADORA1ADORA3ADORA2ABMPR1BP2RY12 | |
| SCHEMBL26534039 | 0.74 | ADORA3 (0.42) | ADORA1ADORA3ADORA2AP2RY12 | |
| SCHEMBL28165438 | 0.73 | ADORA1 (0.45) | ADORA1ADORA3ADORA2AADORA2B | |
| SCHEMBL20149801 | 0.73 | PRMT6 (0.49) | PRMT6ADORA1ADORA3BMPR1BP2RY12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8637475-B1 | Modified 2′ and 3′ nucleoside prodrugs for treating flaviviridae infections | IDENIX PHARMACEUTICALS, INC. (US) | 2014-01-28 | — | — | US | disclosed |
| US-20130330297-A1 | MODIFIED 2' AND 3'-NUCLEOSIDE PRODRUGS FOR TREATING FLAVIVIRIDAE INFECTIONS | IDENIX PHARMACEUTICALS, INC. (US) | 2013-12-12 | — | — | US | disclosed |
| US-20130149283-A1 | METHODS AND COMPOSITIONS FOR TREATING HEPATITIS C VIRUS | UNIVERSITA DEGLI STUDI DI CAGLIARI (IT) | 2013-06-13 | — | — | US | disclosed |
| US-20130017171-A1 | METHODS AND COMPOSITIONS FOR TREATING HEPATITIS C VIRUS | UNIVERSITA DEGLI STUDI DI CAGLIARI (IT) | 2013-01-17 | — | — | US | disclosed |
| US-8343937-B2 | Methods and compositions for treating flaviviruses and pestiviruses | IDENIX PHARMACEUTICALS, INC. (US) | 2013-01-01 | — | — | US | disclosed |
| US-20100316594-A1 | MODIFIED 2' AND 3' NUCLEOSIDE PRODRUGS FOR TREATING FLAVIVIRIDAE INFECTIONS | UNIVERSITY OF CAGLIARI (IT) | 2010-12-16 | — | — | US | disclosed |
| US-7662798-B2 | 2′ and 3′-nucleoside prodrugs for treating Flaviviridae infections | IDENIX PHARMACEUTICALS, INC. (US) | 2010-02-16 | — | — | US | disclosed |
| US-7608600-B2 | Treating hepatitis C virus infections; antivirals have low toxicity to the host; inhibit Flaviviridae polymerase | IDENIX PHARMACEUTICALS, INC. (US) | 2009-10-27 | — | — | US | disclosed |
| US-7608597-B2 | Methods and compositions for treating hepatitis C virus | IDENIX PHARMACEUTICALS, INC. (US) | 2009-10-27 | — | — | US | disclosed |
| US-20070087960-A1 | Treating hepatitis C virus infections; antivirals have low toxicity to the host; inhibit Flaviviridae polymerase | IDENIX PHARMACEUTICALS LLC | 2007-04-19 | — | — | US | disclosed |
| US-20070042990-A1 | 2' and 3'-nucleoside prodrugs for treating Flaviviridae infections | IDENIX PHARMACEUTICALS, INC. | 2007-02-22 | — | — | US | disclosed |
| US-20070037773-A1 | Methods and compositions for treating flaviviruses and pestiviruses | IDENIX PHARMACEUTICALS LLC | 2007-02-15 | — | — | US | disclosed |
| US-20070037735-A1 | 2' and 3'-nucleoside prodrugs for treating Flaviviridae infections | IDENIX PHARMACEUTICALS, INC. | 2007-02-15 | — | — | US | disclosed |
| US-20070032449-A1 | Modified 2' and 3'-nucleoside prodrugs for treating flaviviridae infections | IDENIX PHARMACEUTICALS, INC. | 2007-02-08 | — | — | US | disclosed |
| US-20070032407-A1 | Use treating hepatitis C infection optionally with other viricides such as interferons or ribavirin; low toxicity to the host; use of cytosine-based nucleotides or nucleosides having a 2'-trifluoromethyl-ribose moiety which forms a 5'-phosphate or hydroxy moiety in vivo | IDENIX PHARMACEUTICALS, INC. | 2007-02-08 | — | — | US | disclosed |
| US-20070027104-A1 | Modified 2' and 3'-nucleoside prodrugs for treating Flaviviridae infections | IDENIX PHARMACEUTICALS, INC. | 2007-02-01 | — | — | US | disclosed |
| US-20070027066-A1 | 2' and/or 3' prodrug of 6-modified, 1', 2', 3' or 4'-branched pyrimidine nucleoside for the treatment of a Flaviviridae infection, such as a hepatitis C virus infection; 3'-L-valine ester of .beta.-D-2',6-dimethyl-cytidine; Flaviviridae polymerase inhibitors; low toxicity to host | IDENIX PHARMACEUTICALS, INC. | 2007-02-01 | — | — | US | disclosed |
| US-7169766-B2 | Methods and compositions for treating hepatitis C virus | IDENIX PHARMACEUTICALS, INC. (US) | 2007-01-30 | — | — | US | disclosed |
| US-20070015905-A1 | 2' and 3'-nucleoside prodrugs for treating Flaviviridae infections | IDENIX PHARMACEUTICALS, INC. | 2007-01-18 | — | — | US | disclosed |
| US-7157441-B2 | Methods and compositions for treating hepatitis C virus | IDENIX PHARMACEUTICALS, INC. (US) | 2007-01-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (13 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070042990-A1 | 2' and 3'-nucleoside prodrugs for treating Flaviviridae infections | PNP, NSUN2, HAVCR2 | PRMT6 2866/4885ADORA1 419/4885ADORA3 214/4885 |
| US-20070037735-A1 | 2' and 3'-nucleoside prodrugs for treating Flaviviridae infections | PNP, NSUN2, HAVCR2 | PRMT6 2866/4885ADORA1 419/4885ADORA3 214/4885 |
| US-20070032449-A1 | Modified 2' and 3'-nucleoside prodrugs for treating flaviviridae infections | PNP, UGT1A3, SLC29A2 | PRMT6 2443/4885ADORA1 306/4885ADORA3 132/4885 |
| US-20070027066-A1 | 2' and/or 3' prodrug of 6-modified, 1', 2', 3' or 4'-branched pyrimidine nucleoside for the treatment of a Flaviviridae infection, such as a hepatitis C virus infection; 3'-L-valine ester of .beta.-D-2',6-dimethyl-cytidine; Flaviviridae polymerase inhibitors; low toxicity to host | DCTD, DIMT1, CYP2D6 | PRMT6 671/4885ADORA1 735/4885ADORA3 333/4885 |
| US-20100316594-A1 | MODIFIED 2' AND 3' NUCLEOSIDE PRODRUGS FOR TREATING FLAVIVIRIDAE INFECTIONS | PNP, UGT1A3, SLC29A2 | PRMT6 2355/4885ADORA1 296/4885ADORA3 125/4885 |
| US-20130149283-A1 | METHODS AND COMPOSITIONS FOR TREATING HEPATITIS C VIRUS | HAVCR2, HCCS, PYGL | PRMT6 2675/4885ADORA1 921/4885ADORA3 482/4885 |
| US-20070027104-A1 | Modified 2' and 3'-nucleoside prodrugs for treating Flaviviridae infections | PNP, UGT1A3, SLC29A2 | PRMT6 2443/4885ADORA1 306/4885ADORA3 132/4885 |
| US-20130330297-A1 | MODIFIED 2' AND 3'-NUCLEOSIDE PRODRUGS FOR TREATING FLAVIVIRIDAE INFECTIONS | PNP, UGT1A3, UGT2B7 | PRMT6 2353/4885ADORA1 408/4885ADORA3 178/4885 |
| US-20070032407-A1 | Use treating hepatitis C infection optionally with other viricides such as interferons or ribavirin; low toxicity to the host; use of cytosine-based nucleotides or nucleosides having a 2'-trifluoromethyl-ribose moiety which forms a 5'-phosphate or hydroxy moiety in vivo | NUDT1, MTAP, HAVCR2 | PRMT6 3104/4885ADORA1 251/4885ADORA3 96/4885 |
| US-20070037773-A1 | Methods and compositions for treating flaviviruses and pestiviruses | MTAP, PHOSPHO1, PNP | PRMT6 2073/4885ADORA1 1885/4885ADORA3 1821/4885 |
| US-20070087960-A1 | Treating hepatitis C virus infections; antivirals have low toxicity to the host; inhibit Flaviviridae polymerase | HAVCR2, UGT1A3, UGT1A1 | PRMT6 3062/4885ADORA1 635/4885ADORA3 308/4885 |
| US-20130017171-A1 | METHODS AND COMPOSITIONS FOR TREATING HEPATITIS C VIRUS | HAVCR2, HCCS, PYGL | PRMT6 2675/4885ADORA1 921/4885ADORA3 482/4885 |
| US-20070015905-A1 | 2' and 3'-nucleoside prodrugs for treating Flaviviridae infections | PNP, NSUN2, HAVCR2 | PRMT6 2866/4885ADORA1 419/4885ADORA3 214/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.